ZA201001530B - A medicament - Google Patents
A medicament Download PDFInfo
- Publication number
- ZA201001530B ZA201001530B ZA201001530A ZA201001530A ZA201001530B ZA 201001530 B ZA201001530 B ZA 201001530B ZA 201001530 A ZA201001530 A ZA 201001530A ZA 201001530 A ZA201001530 A ZA 201001530A ZA 201001530 B ZA201001530 B ZA 201001530B
- Authority
- ZA
- South Africa
- Prior art keywords
- paracetamol
- glaucoma
- administered
- patient
- treatment
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 78
- 229960005489 paracetamol Drugs 0.000 claims description 77
- 208000010412 Glaucoma Diseases 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 16
- 239000002997 ophthalmic solution Substances 0.000 claims description 12
- 229940054534 ophthalmic solution Drugs 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000004087 cornea Anatomy 0.000 description 18
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 241000283973 Oryctolagus cuniculus Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 9
- 230000004907 flux Effects 0.000 description 8
- 230000035699 permeability Effects 0.000 description 8
- 238000009792 diffusion process Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 210000001508 eye Anatomy 0.000 description 5
- 230000004410 intraocular pressure Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 2
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000011067 equilibration Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 210000005227 renal system Anatomy 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 238000001134 F-test Methods 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000143252 Idaea infirmaria Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010061323 Optic neuropathy Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- FPWNQPQTICPCOM-UHFFFAOYSA-N acetonitrile;propan-2-ol Chemical compound CC#N.CC(C)O FPWNQPQTICPCOM-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 231100000478 corneal permeability Toxicity 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910001867 inorganic solvent Inorganic materials 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA201001530A ZA201001530B (en) | 2007-08-07 | 2010-03-03 | A medicament |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA200706585 | 2007-08-07 | ||
| ZA201001530A ZA201001530B (en) | 2007-08-07 | 2010-03-03 | A medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201001530B true ZA201001530B (en) | 2010-10-27 |
Family
ID=40341822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA201001530A ZA201001530B (en) | 2007-08-07 | 2010-03-03 | A medicament |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20110098359A1 (zh) |
| EP (1) | EP2203165B1 (zh) |
| CN (1) | CN101815513B (zh) |
| AU (1) | AU2008285244B2 (zh) |
| ES (1) | ES2424872T3 (zh) |
| PT (1) | PT2203165E (zh) |
| WO (1) | WO2009019555A2 (zh) |
| ZA (1) | ZA201001530B (zh) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2646773B1 (fr) * | 1989-05-12 | 1994-05-13 | Chauvin Sa Laboratoire | Composition pharmaceutique a base de paracetamol |
| GB9704524D0 (en) * | 1997-03-05 | 1997-04-23 | Smithkline Beecham Plc | Composition |
| IT1313579B1 (it) * | 1999-07-30 | 2002-09-09 | Acraf | Composizione farmaceutica liquida a base di paracetamolo. |
| US20030185892A1 (en) * | 2001-08-17 | 2003-10-02 | Bell Steve J. D. | Intraocular delivery compositions and methods |
| US7671052B2 (en) * | 2004-10-05 | 2010-03-02 | Adolor Corporation | Phenyl derivatives and methods of use |
-
2008
- 2008-07-30 US US12/672,475 patent/US20110098359A1/en not_active Abandoned
- 2008-07-30 ES ES08788957T patent/ES2424872T3/es active Active
- 2008-07-30 EP EP08788957.2A patent/EP2203165B1/en not_active Not-in-force
- 2008-07-30 PT PT87889572T patent/PT2203165E/pt unknown
- 2008-07-30 CN CN2008801099375A patent/CN101815513B/zh not_active Expired - Fee Related
- 2008-07-30 WO PCT/IB2008/001979 patent/WO2009019555A2/en active Application Filing
- 2008-07-30 AU AU2008285244A patent/AU2008285244B2/en not_active Ceased
-
2010
- 2010-03-03 ZA ZA201001530A patent/ZA201001530B/en unknown
-
2013
- 2013-10-02 US US14/044,004 patent/US9072704B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101815513A (zh) | 2010-08-25 |
| US9072704B2 (en) | 2015-07-07 |
| EP2203165A2 (en) | 2010-07-07 |
| WO2009019555A2 (en) | 2009-02-12 |
| EP2203165A4 (en) | 2011-10-05 |
| PT2203165E (pt) | 2013-08-22 |
| US20140045946A1 (en) | 2014-02-13 |
| CN101815513B (zh) | 2012-11-14 |
| AU2008285244A1 (en) | 2009-02-12 |
| EP2203165B1 (en) | 2013-05-22 |
| AU2008285244B2 (en) | 2015-02-19 |
| ES2424872T3 (es) | 2013-10-09 |
| US20110098359A1 (en) | 2011-04-28 |
| WO2009019555A3 (en) | 2009-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lopez-de la Mora et al. | Role and new insights of pirfenidone in fibrotic diseases | |
| Carr et al. | A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis | |
| Okabe et al. | Biodegradable intrascleral implant for sustained intraocular delivery of betamethasone phosphate | |
| Bian et al. | Dexamethasone drug eluting nanowafers control inflammation in alkali-burned corneas associated with dry eye | |
| KR20240049636A (ko) | 비정상적 신생혈관이 있는 안구 질환 치료를 위한, 닌테다닙을 사용하는 조성물 및 방법 | |
| Hao et al. | Mechanisms underlying the promotion of functional recovery by deferoxamine after spinal cord injury in rats | |
| Van Der Bijl et al. | Effects of three penetration enhancers on transcorneal permeation of cyclosporine | |
| WO2006091038A1 (en) | Pharmaceutical composition for treating avellino cornea dystrophy comprising blood plasma or serum | |
| US10314914B2 (en) | Iodophor composition and methods of use | |
| Anisimova et al. | Effect of NSAIDs on pupil diameter and expression of aqueous humor cytokines in FLACS versus conventional phacoemulsification | |
| Yamada et al. | Aqueous humor levels of topically applied levofloxacin, norfloxacin, and lomefloxacin in the same human eyes | |
| Jackowski et al. | Alterations in serotonin and neuropeptide Y content of cerebrovascular sympathetic nerves following experimental subarachnoid hemorrhage | |
| Douglas et al. | Ocular toxicity and distribution of subconjunctival and intravitreal rapamycin in horses | |
| Papp et al. | The safety and tolerability of topically delivered kynurenic acid in humans. A phase 1 randomized double-blind clinical trial | |
| AU2008285244B2 (en) | A medicament | |
| Alakhali et al. | Evaluation of therapeutic drug monitoring of cyclosporine and tacrolimus in kidney transplant patients | |
| Ye et al. | Effect of ligustrazine on preventing contrast-induced nephropathy in patients with unstable angina | |
| van der Bijl et al. | In vitro transcorneal penetration of metronidazole and its potential use as adjunct therapy in Acanthamoeba keratitis | |
| CA3153424A1 (en) | Lyophilized composition comprising (s)-isopropyl 2-((s)-2-acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5-oxohexanoate for intravenous administration and the use thereof | |
| Zhao et al. | Comparative study of ocular pharmacokinetics of gatifloxacin between continuous lavage and hourly topical instillation in rabbits | |
| Huang et al. | An inhibitor of claudin-5 interactions, M01, alleviates neuroinflammation and vasogenic edema after blood–spinal cord barrier dysfunction | |
| Kim et al. | Oral steroid therapy as an adjuvant treatment for severe epidemic keratoconjunctivitis in patients younger than 3 years | |
| Van Eyk et al. | In vitro diffusion of the immunosuppressant tacrolimus through human and rabbit corneas | |
| Schoellhorn et al. | Localized subcutaneous acute febrile neutrophilic dermatosis in a dog | |
| van Eyk et al. | In vitro transcorneal diffusion of the antimicrobial macrolides azithromycin and clarithromycin and the impact on microbial keratitis |